MedTrace Logo

GIP and GLP-1 in Type 1 Diabetes

NCT01739283 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-07-13

No results posted yet for this study

Summary

Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and hypoglycemia in type 1 diabetes.

Conditions

Interventions

OTHER

GIP

OTHER

GLP-1

OTHER

Saline

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Mikkel Christensen

    lead OTHER

Principal Investigators

  • Mikkel Christensen, MD · University Hospital, Gentofte, Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-04-30
Completion
2013-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01739283 on ClinicalTrials.gov